| Title |
Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, December 2005
|
| DOI | 10.1007/s10549-005-9009-7 |
| Pubmed ID | |
| Authors |
Susan Cleator, Anna Tsimelzon, Alan Ashworth, Mitch Dowsett, Timothy Dexter, Trevor Powles, Susan Hilsenbeck, Helen Wong, C. Kent Osborne, Peter O’Connell, Jenny C. Chang |
| Abstract |
Doxorubicin and cyclophosphamide (Adriamycin/cytoxan, AC) is a standard chemotherapy regimen for breast cancer, but de novo resistance is frequent. We hypothesized that gene expression profiles predictive of AC response may be different from our previously published patterns with docetaxel. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| United States | 1 | 2% |
| Canada | 1 | 2% |
| Unknown | 41 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 27% |
| Other | 5 | 11% |
| Student > Master | 4 | 9% |
| Professor | 4 | 9% |
| Student > Bachelor | 4 | 9% |
| Other | 9 | 20% |
| Unknown | 6 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 27% |
| Biochemistry, Genetics and Molecular Biology | 9 | 20% |
| Agricultural and Biological Sciences | 9 | 20% |
| Psychology | 3 | 7% |
| Neuroscience | 2 | 5% |
| Other | 3 | 7% |
| Unknown | 6 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 August 2019.
All research outputs
#6,911,493
of 22,663,150 outputs
Outputs from Breast Cancer Research and Treatment
#1,494
of 4,612 outputs
Outputs of similar age
#35,925
of 146,202 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#13
of 39 outputs
Altmetric has tracked 22,663,150 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 4,612 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 146,202 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.